Metahexamide (INN) is an anti-diabetic drug from the group of sulfonylureas. It is long-acting and belongs to the first-generation cyclohexyl-containing sulfonylureas. It was first described in 1959.[1]
Names | |
---|---|
Preferred IUPAC name
3-Amino-N-(cyclohexylcarbamoyl)-4-methylbenzene-1-sulfonamide | |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
ECHA InfoCard | 100.008.434 |
KEGG | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C14H21N3O3S | |
Molar mass | 311.4 g/mol |
Pharmacology | |
A10BB10 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
References
edit- ^ Moss JM, Delawter D (September 1959). "Metahexamide in diabetes therapy". Ann NY Acad Sci. 82 (2): 614–7. doi:10.1111/j.1749-6632.1959.tb44940.x. PMID 14424617.